Corona Remedies Secures EAEU-GMP Certification for Bhayla Facility
Filing Summary
Corona Remedies Limited has received the EAEU-GMP certification for its finished dosage facility in Bhayla, Gujarat. This certification allows the company to enter the pharmaceutical markets of Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan under a B2B model. The EAEU market is valued at approximately USD 25 billion. The certification supports Corona’s focus on Women’s Health, Cardio-Diabetes, Pain Management, and Urology. The company emphasizes its commitment to global regulatory standards and operational excellence.
On January 21, 2026, Corona Remedies Limited announced the receipt of the EAEU-GMP certification for its finished dosage facility located in Bhayla, Gujarat. This certification, granted by the Eurasian Economic Union, enables the company to access pharmaceutical markets in Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan. The EAEU market is estimated to be worth approximately USD 25 billion.
The certification aligns with Corona’s business model, allowing it to operate under a B2B framework in these regions. The company focuses on four key therapeutic areas: Women’s Health, Cardio-Diabetes, Pain Management, and Urology. The certification is part of Corona’s strategy to enhance its global presence and adhere to international regulatory standards.
Corona’s CEO and Managing Director, Nirav K. Mehta, stated that the certification reflects the company’s commitment to quality healthcare across geographical boundaries. The company emphasizes its operational excellence and adherence to global regulatory standards, positioning itself as a trusted international partner in pharmaceutical innovation.
Corona Remedies is one of the few pharmaceutical manufacturers in Gujarat to receive this certification, highlighting its rigorous quality systems and commitment to delivering safe and effective medicines. The company’s guiding principle, “One World, One Quality,” underscores its mission to provide trusted healthcare solutions both in India and globally.
Corona Remedies Limited is a domestic, branded pharmaceutical formulation company engaged in developing, manufacturing, and marketing products in various therapeutic areas, including women’s healthcare, cardio-diabetes, pain management, and urology. The company is recognized as the fastest-growing among the top 30 companies in the Indian Pharmaceutical Market in terms of domestic sales. It is committed to delivering high-quality, accessible healthcare solutions and actively contributes to community well-being through structured public health and awareness initiatives.